Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

0089 Pre-Sleep Inorganic Nitrate Use and Sleep Quality: A Pilot Study
Venkatesh, Viswanath , Greenlund, Ian M. , Allgauer, Chieko, Migliaccio, Gianna, Rounds, Garret, StLouis, Erik, Bock, Joshua M. , StLouis, Erik, Somers, Virend K.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A40-A41

10.1093/sleep/zsaf090.0089 Get It

Abstract Introduction Poor sleep quality is bidirectionally associated with cardiovascular and neurocognitive disorders. Preclinical data implicate nitric oxide (NO) in the onset, and maintenance, of sleep. Acute inorganic nitrate supplementation increases NO bioavailability via serial reduction for >12hrs. We tested if objective (Aim 1) or subjective (Aim 2) sleep quality was better following acute, pre-sleep nitrate supplementation relative to a placebo. Methods Seven non-shift working adults (4F/3M, 40±8yrs, 25.8±1.6kg/m2) with no history of sleep, cardiovascular, or neurocognitive disorders completed three overnight polysomnography (PSG) visits with time in bed standardized to 2200-0600hrs. Visit 1 was for acclimation and screening for sleep-disordered breathing. On Visits 2 and 3, participants consumed beetroot juice containing (6.45mmol) or devoid of (0mmol) inorganic nitrate at 2200 using a randomized, cross-over study design. PSG-derived outcomes included slow-wave (SWS) and rapid eye-movement (REM) sleep, sleep efficiency, and wake after sleep onset (WASO). Subjective sleep quality assessments were administered in-laboratory including a 0-10 scale, the Stanford Sleepiness Scale (SSS), and performance with mental arithmetic shortly after awakening. Results No participant demonstrated evidence for sleep-disordered breathing (apnea-hypopnea index = 1.7±0.9events/hr). Total sleep time (TST, 434±17 vs. 412±19min), sleep efficiency (89±3 vs. 85±4%), as well as SWS duration (75±10 vs. 66±9min) and percent of TST (17±2 vs. 16±2%) were higher after nitrate relative to the placebo (p< 0.05 for all). WASO (47±16 vs. 62±19min, p< 0.05) was lower after nitrate versus placebo and no differences were seen in REM sleep duration (131±23 vs. 117±12min, p=0.45) nor percent of TST (30±5 vs. 29±3%, p=0.80). Neither the 0-10 scale (6.7±0.5 vs. 6.8±0.6units, p=0.84), SSS (2.6±0.4 vs. 2.5±0.3units, p=0.68), or arithmetic performance (82±3 vs. 81±5% correct, p=0.85) differed post-nitrate compared to post-placebo. Conclusion These data suggest that acutely increasing nocturnal NO levels via pre-sleep inorganic nitrate supplementation improves objective indices of sleep quality in healthy adults. However, greater amounts of nitrate or prolonged supplementation (weeks) may be needed to improve perceived sleep quality. Support (if any) The National Institutes of Health (K12 AR084222 to JMB, R01s HL160619 and HL65176 to VKS), Sleep Research Society Foundation (CDA 038-JP-23 to JMB), and the American Heart Association (24POST1241616 to IMG).
0892 Prodromal Parkinsonism in post-9/11 Veterans with Probable REM Sleep Behavior Disorder: A Pilot Study
White, Taryn, Broadway, Dakota, Jackson, George R. , Singh, Supriya, Li, Ruosha , St-Louis, Erik, Marsh, Laura , Jorge, Ricardo E. , Jones, Melissa B.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A387-A388

10.1093/sleep/zsaf090.0892 Get It

Abstract Introduction Rapid eye movement (REM) sleep behavior disorder (RBD) is the single strongest predictor of Parkinson’s disease (PD) risk. Given neurotrauma and psychiatric morbidity, the aging post-9/11 Veteran cohort is a target population for understanding probable RBD frequency and neuroprotection opportunities. We previously reported over 50% of post-9/11 Veterans screened positive for probable RBD. We aimed to examine frequencies of prodromal PD markers and polysomnography (PSG)-confirmed RBD in post-9/11 Veterans. Methods Veterans with probable RBD based on the single-question RBD screen (n=12) were recruited from the Translational Research Center for Traumatic Brain Injury (TBI) and Stress Disorders (TRACTS) Houston cohort. Participants were assessed for subthreshold parkinsonism (Unified Parkinson’s Disease Rating Scale-III Motor score >3, excluding action tremor), olfactory loss (12-item Sniffin’ Sticks), TBI exposures, autonomic symptoms, orthostasis, excessive daytime sleepiness, post-traumatic stress disorder (PTSD), and psychiatric comorbidities. PSG studies were conducted per American Academy of Sleep Medicine guidelines. A board-certified sleep physician confirmed the presence of REM sleep without atonia. We compared the frequency of prodromal marker positivity between participants with and without subthreshold parkinsonism. Results All 12 participants were male (6 [50%] Black, 3 [25%] Hispanic) with a mean (SD) age of 44.4 ± 6.7 years. PSG data (n=10) revealed REM sleep without atonia in 5 (50%), moderate obstructive sleep apnea (OSA) in 2 (20%), and severe OSA in 2 (20%) participants. Five (41.6%) participants had mild motor dysfunction suggestive of subthreshold parkinsonism on the UPDRS-III (M±SD score of 8.6 ± 5.9), while 7 participants had normal or low UPDRS-III ratings (2.3 ± 1.3; p=0.02). Veterans with subthreshold parkinsonism had lower Sniffin’ Sticks scores than those without (M±SD 9.4 ± 2.07 vs. 11.29 ± 0.76; 95% CI: 0.01–3.76, p=0.049). Conclusion This pilot study suggests that motor and olfactory prodromal PD markers are frequent in post-9/11 Veterans with probable RBD. Larger prospective cohort studies are required to further quantify REM sleep without atonia and assess synuclein-specific biomarkers in this population. Support (if any) Center for Alzheimer’s and Neurodegenerative Diseases at Baylor College of Medicine [MJ]; VA CSR&D (#IK2CX002363-01A1) [MJ]; VA RR&D (B9268-X) [RJ]; NIH/NIA/NINDS (U19-AG071754 & R34-AG056639) [ES]; and AASM [ES].
0647 A Prospective Pilot Study of Obstructive Sleep Apnea Among Greek Americans in the Upper Midwest
Greenlund, Ian M. , St‐Louis, Etienne , Somers, Virend K., Kantas, Dimitrios, Mohamed, Essa A. , Karim, Shahid , Li, Jingen, StLouis, Erik

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A282-A283

10.1093/sleep/zsaf090.0647 Get It

Abstract Introduction Obstructive sleep apnea (OSA) has been linked to metabolic syndrome, heart failure, atrial fibrillation, and hypertension. Although ethnic differences related to OSA have been reported, no studies have evaluated the impact of OSA among Greek-Americans. Methods This prospective cross-sectional study, in partnership with the Greek-American community, employed a community-based participatory research framework. Individuals who were of Greek descent and ≥18 years of age were recruited. Anthropometric measurements, Mallampati score, BMI, and adiposity (DEXA scan) were determined. All subjects were administered the Epworth Sleepiness Scale (ESS) and underwent home sleep apnea test (WatchPAT ONE), using a desaturation threshold of 4% as diagnostic. Descriptive statistics were computed to describe the study population and data were analyzed using the student t-test and chi-squared test. Results A 76 Greeks, 34 males (44.8%) and 42 females (55.2%), were enrolled in this study with a mean ± SD age and BMI of 42.6±17.5 years (p< 0.01) and 27±6 kg/m2, respectively. A total of 22 (29%; 14 males and 8 females) individuals were diagnosed with OSA, of whom 13 (59.1%) had mild, 5 (22.7%) had moderate and 4 (18.2%) had severe OSA. Subjects with OSA were older (58.8±11.9 vs 36.0±15.1 years, p< 0.01), had higher BMI (32±7 vs 25±4 kg/m2, p< 0.01), larger neck circumference (40±4 vs 35±4 cm, p< 0.01) and higher waist-to-hip ratio (0.94±0.08 vs 0.84±0.07, p< 0.01). Body fat percentage was significantly higher among those with versus without OSA (38.8±9.6 vs 34.0±9.2%; p=0.04) while Mallampati and ESS scores were similar. Conclusion This is the first study to assess sleep metrics of Greek-Americans suffering from OSA. Characteristics of those with OSA are similar to other populations. However, the commonly used ESS screening appears to have limited application in this cohort of subjects. Greek-Americans with elevated body fat percentage when associated with concurrent OSA, may be at higher risk of developing cardiometabolic adverse events. Additional studies are required to further elucidate the effect of sleep physiology, cardiometabolic dysfunction and health outcomes. Support (if any) This work was supported by a grant from Sleep Number Corporation to Mayo Clinic, by WatchPATs provided by Zoll Itamar, and by the National Institutes of Health HL160619.
0609 Cardiovascular Disease Risk Factors in Former National Football League Players: Impact of Obstructive Sleep Apnea
Greenlund, Ian M. , Forgione, Marc A., Perryman, Jonathan, Gergen, David, Martinez-Ferrate, Rodolfo, Covassin, Naima , Bukartyk, Jan , Roberts, Arthur J., Perryman, Jonathan, Bock, Joshua M. , Somers, Virend K.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A266-A266

10.1093/sleep/zsaf090.0609 Get It

Abstract Introduction Cardiovascular disease (CVD) remains the leading cause of death in the United States. We previously showed a high prevalence of obstructive sleep apnea (OSA) among former National Football League (NFL) players. Further, we hypothesized that post-career OSA impacts CVD risk among retired professional athletes, even though these former NFL players are often near peak physical fitness for a significant portion of their lifespan. The Living Heart Foundation Heart-Obesity-Prevention-Education Group aimed to provide an in-depth health assessment for CVD risk factors among former NFL players to examine the role of OSA on blood pressure (BP) and echocardiographic measurements. Methods Forty-three former NFL players completed an at-home sleep study and outpatient health assessment to determine CVD risk including office BP and transthoracic echocardiogram (TTE) measurements. Seated BP readings were made in triplicate, TTE measurements, including ejection fraction, left atrial size, left ventricular size and thickness, and ascending aortic diameter, were obtained in 17 former NFL players without OSA (age: 46±10 years, BMI: 32±5 kg/m2, apnea-hypopnea index: 3±1 events/hour) and 26 with OSA (age: 51±9 years, BMI: 33±5 kg/m2, apnea-hypopnea index: 17±12 events/hour). Independent sample t-tests were utilized to determine differences in blood pressure and TTE measurements between OSA and non-OSA groups (α=0.05). Results Systolic BP was similar in non-OSA vs. OSA groups (131±12 vs. 135±16 mmHg, p=0.443), while diastolic BP was higher in former NFL players with OSA (78±8 vs. 86±9 mmHg, p=0.007). Ejection fraction, left atrial size, left ventricular size, and left ventricular thickness were similar between groups (p>0.05 for all). However, ascending aortic diameter was modestly larger in former NFL players with OSA (3.3±0.19 vs. 3.5±0.40 cm, p=0.048). Conclusion These findings suggest OSA may be a primary driver of increased BP and increased aortic diameter in former NFL players, and impact cardiac structural health, suggesting augmented CVD risk in former NFL players. Future work is warranted to investigate impact of race and player position on OSA-mediated CVD risk in retired NFL players. Support (if any) NFL Players Association, NIH T32-DK007013, and the American Heart Association (24POST1241616)
0851 Effectiveness and Safety of Low-Sodium Oxybate in Idiopathic Hypersomnia Participants: Results from the DUET Study
Cairns, Alyssa , Schneider, Logan , Nichols, Deborah A. , Steininger, Teresa L. , Kirby, Melanie, Akerman, Sarah , Alexander, Jessica, Whalen, Marisa, Ruoff, Chad , Ruoff, Chad M , Plante, David T. , Fuller, Douglas, Kirby, M

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A369-A369

10.1093/sleep/zsaf090.0851 Get It

Abstract Introduction Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on daytime and nighttime symptoms, including excessive daytime sleepiness (EDS) and polysomnography in participants with idiopathic hypersomnia (IH) or narcolepsy. Data presented are from the IH cohort. Methods DUET included screening (with 2-week washout for oxybate users), 8-day baseline (BL), 2- to 8-week LXB titration, 2-week stable-dose, 8-day end-of-treatment (EOT), and 2-week safety follow-up periods. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Secondary endpoints for the IH cohort included change in Idiopathic Hypersomnia Severity Scale (IHSS) total score, Patient Global Impression of Change (PGIc)−overall IH disease, PGIc−sleep inertia, and Patient Global Impression of Severity (PGIs)−sleep inertia. Exploratory endpoints included IHSS component scores (daytime functioning, sleep inertia). Primary and key secondary (IHSS total score) endpoints were controlled for multiplicity with sequential testing; all other P-values are considered nominal. Results Forty-six people with IH enrolled and were dosed with LXB; 40 were completers. Enrolled participants were mostly female (80.4%) and White (84.8%), with a mean (SD) age of 38.1 (11.8) years. For completers, BL mean (SD) ESS score and IHSS total score were 16.5 (2.7) and 32.9 (7.1), respectively; least-squares mean (LSM) (SE) changes from BL to EOT were −8.4 (0.7), P<.0001 and −15.5 (1.5), P<.0001. BL mean (SD) IHSS component scores for daytime functioning and sleep inertia were 17.7 (4.2) and 10.7 (3.1), respectively; LSM (SE) changes from BL to EOT were −8.8 (1.0), P<.0001 and −4.8 (0.4), P<.0001. At EOT, most participants reported improvement (very much, much, minimally) on PGIc−overall IH disease (94.6%) and PGIc−sleep inertia (81.1%). At BL, 25.0% of participants reported sleep inertia severity as very mild/mild/not present on PGIs–sleep inertia vs 59.0% at EOT. Treatment-emergent adverse events were consistent with the known safety profile of LXB. Conclusion People with IH taking open-label LXB showed improvements in EDS and sleep inertia (decreased ESS and IHSS component scores) and reported reduced multi-symptom burden (decreased IHSS total scores and improved PGIc/PGIs ratings). Support (if any) Jazz Pharmaceuticals
0689 Exploratory Study of the Effect of Alcohol on Home Sleep Apnea Testing Utilizing Peripheral Arterial Tone
Schnell, Aaron L, Ruoff, Chad , Tashman, Yasemin, Goswami, Umesh , Martin, Kari A. , Petersen, Ann M. , Haley, Caitlin C., Rogers, Kimberly, Lizak, Matthew, Schaal, Caroline J, Lamas, Christopher M, Lyng, Philip J., Krahn, Lois E., Ruoff, Chad M , Schnell, Aaron L, Garrett, Ashley L. , Goswami, Umesh, Petersen, Ann M, Yee, Claire

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A300-A300

10.1093/sleep/zsaf090.0689 Get It

Abstract Introduction A previously published case report suggested that alcohol might cause false-negative results in home sleep apnea testing (HSAT) utilizing Peripheral Arterial Tonometry (PAT). Alcohol is consumed by nearly a third of people globally. Based on this, along with rapid growth in PAT HSAT utilization, we aimed to prospectively study the interaction between alcohol consumption and PAT HSAT technology. We hypothesized that alcohol use would significantly attenuate sleep disordered breathing metrics in contrast to existing literature suggesting alcohol may exacerbate sleep apnea. Methods We planned to recruit subjects (N=100) from Mayo Clinic Arizona sleep clinic who were being evaluated for sleep-disordered breathing and elected to undergo home sleep apnea testing (WatchPAT ONE). Participants were required to report social alcohol use (no more than 1-3 drinks per day). The first and second home sleep apnea test were conducted on separate nights (night 1: without alcohol; night 2: with alcohol). Patients also completed a questionnaire, detailing their normal alcohol intake as well as intake during the respective sleep tests. Statistical analysis included paired sample t-test as well as a descriptive analysis. Results A total of 75 subjects were recruited (mean age [± SD] 56.8 ± 11.9; 90.7% male; mean BMI 29.8 ± 5.8) and 56 patients completed both sleep tests. The mean apnea hypopnea index (AHI) was not statistically different (p=0.784) between night 1 and night 2 (without alcohol: 19.6/hour ± 21.0; with alcohol: 19.3 ± 21.5, respectively). Similarly, no statistically significant difference was found in the AHI during REM and NREM sleep. Conclusion Preliminary data does not suggest a statistically significant difference in AHI without or with alcohol. While no significant change in AHI was observed, this study highlights the need for further investigation into the impact alcohol may have on PAT technology. Further analyses and data enrichment are underway. Support (if any) Mayo Foundation
0714 Fully Telehealth vs. Fully Face-to-Face Management of Obstructive Sleep Apnea: A Comparative Study of CPAP Compliance
Seckin, Z.I., Morgenthaler, Timothy I.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A310-A311

10.1093/sleep/zsaf090.0714 Get It

Abstract Introduction Obstructive sleep apnea (OSA) is effectively treated with continuous positive airway pressure (CPAP), but access remains a challenge. The COVID-19 pandemic accelerated telehealth, offering a convenient alternative to in-person visits for OSA evaluation and treatment initiation. This study compares patients managed entirely via video telehealth to those managed entirely in person. We hypothesize that virtual are as effective as in-person evaluations in managing most OSA patients. Methods The study is approved by the Mayo Clinic IRB. We retrospectively studied adult patients diagnosed with OSA requiring CPAP initiation between June 2020–2023. Data collected included baseline demographics, home sleep apnea testing (HSAT) results, polysomnography (PSG) results, Epworth Sleepiness Scale (ESS) scores, OSA severity, compliance results, other relevant comorbidities (i.e. cardiovascular diseases). Visit type categorized as “in-person” for patients who had both initial and follow-up appointments in-person, while “telehealth” group included patients who had both appointments virtually. Results Of 59 patients, 33 had telehealth (56%). The groups had similar medians in age (66 vs 62), sex (73% vs 67% male), and BMI (30 vs 32). There was no significant difference in median ESS scores (8 vs 7, p=0.7). However, the severity of OSA (moderate to severe) was higher in the in-person group (73% vs 45%, p=0.03). When baseline sleep study data was investigated, there were no differences in AHI and average SpO2 values measured by HSAT or PSG between the two groups (p>0.05 for all). CPAP compliance was significantly higher in the telehealth group compared to in-person (78% vs 40%, OR: 5.5, 95% CI: 1.7-17.1, p=0.003). Virtual visit type was the only independent predictor of compliance (p=0.006), after adjusting for age, BMI, comorbidities and OSA severity in multivariate analysis. However, there was no difference in average daily CPAP usage (6:39 vs 7:18, p=0.5) and percentage of days with usage >4 hours (91% vs 95, p=0.5). Median AHI after treatment improved in both groups, with no significant difference between groups (1.7 vs 2.4, p=0.8). Conclusion Telehealth offers a successful alternative to in-person visits for OSA evaluation, with similar outcomes and significantly better compliance, enhancing OSA management. Support (if any)
0722 Automatic Activation of Transvenous Phrenic Nerve Stimulation for Central Sleep Apnea Results in High Nightly Usage
Khan, Meena , Germany, Robin , Khayat, Rami , Morgenthaler, Timothy I. , McKane, Scott , Costanzo, Maria Rosa

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A314-A314

10.1093/sleep/zsaf090.0722 Get It

Abstract Introduction Adherence with mask-based therapies remains a significant challenge for optimal treatment of patients with sleep disordered breathing. Transvenous phrenic nerve stimulation (TPNS) to treat central sleep apnea offers a novel, automated approach to enhance nightly adherence by initiating therapy based on patient-specific programmed conditions such as sleep schedule, activity, and body position. Therapy automatically pauses when the patient sits up or changes position, facilitating re-initiation of sleep. This research aimed to determine the degree of adherence achieved with TPNS’s automated activation approach. Methods Device data from 128 remedē® System Pivotal Trial participants were analyzed to calculate hours of therapy activation. Daily use from device data within the 14 days prior to scheduled visits were used to calculate median daily hours of therapy per patient, and subsequently the overall median daily use for all patients. Therapy duration was defined as the sum of time of delivered therapy when all conditions to activate therapy were met between the first time therapy came on to the last time off during the night, excluding time when activity or body position did not meet the programmed criteria for therapy activation. Results The median [Q1-Q3] nightly therapy duration at 6, 12, 18, and 24 months was 5.9 [4.9-6.6], 5.7 [5.0-6.8], 6.0 [5.3-6.8], and 5.9 [4.9-6.5] hours, respectively. Using a definition for adequate therapy as the percentage of patients with usage ≥4 hours/night for at least 70% of nights, 86%, 82%, 83%, and 90% of patients met the criteria at these visits. Only two patients (< 2%) who had therapy activated discontinued treatment prior to 6 months due to stimulation intolerance. Patients with median delivered therapy ≥4 hours/night reported more quality of life improvement than patients with < 4 hours of therapy. Conclusion The automatic activation of TPNS therapy resulted in a higher duration of nightly usage and higher rate of adequate delivered therapy than generally are reported for mask-based therapies. This high usage may yield a greater overall reduction in central sleep apnea burden over the whole night compared to therapies that require the patient to initiate the therapy. Support (if any) ZOLL Respicardia, Inc.
0860 Subjective Sleep Quality with Low-Sodium Oxybate Treatment in Narcolepsy: Results from the DUET Study
Mignot, Emmanuel, Ruoff, Chad , Nichols, Deborah A. , Steininger, Teresa L. , Kirby, Mary, Whalen, Marisa, Schneider, Logan , Ruoff, Chad M , Sangal, R. Bart , Fuller, Douglas

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A373-A373

10.1093/sleep/zsaf090.0860 Get It

Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes including sleep quality (using polysomnography [PSG] and self-reported questionnaires) in participants with narcolepsy or idiopathic hypersomnia. Data reported here are from the narcolepsy cohort. Methods DUET included a screening period (with 2-week washout for current oxybate users), an 8-day baseline (BL) period, a 2- to 8-week LXB titration period, a 2-week stable-dose period (SDP), an 8-day end-of-treatment (EOT) period, and a 2-week safety follow-up. Participants underwent nocturnal PSG (ad libitum protocol) at BL and EOT. The Karolinska Sleepiness Scale (KSS) was administered 90 minutes post-awakening from PSG to measure situational sleepiness (9-point scale; 1=“extremely alert” to 9=“extremely sleepy, can’t keep awake”). Participants completed an electronic sleep diary (eDiary) daily during the BL and EOT periods, including questions regarding nightly sleep patterns, total sleep time (TST), sleep quality (5-point scale; “very good” to “very poor”), and how rested/refreshed the participant felt upon awakening (5-point scale; “very well” to “not at all”). Completion of ≥5 eDiary days during the 8-day assessment before PSG visits was required for analysis. eDiary and KSS data were analyzed in the completer set (enrolled participants who were dosed with LXB and completed SDP and PSG at EOT). Results Fifty-five participants with narcolepsy (type 1, n=26; type 2, n=29) enrolled (completer set, n=34). Most were female (40/55; 73%) and White (44/55; 80%); mean (SD) age was 33.4 (12.9) years. Mean (SD) self-reported nocturnal TST at BL (n=32) and EOT (n=20) was 8.1 (1.6) and 8.3 (0.9) hours, respectively. The percent of participants rating their sleep quality as “very good”/“good” increased from 15.6% (BL) to 70.0% (EOT). The percent of participants with rested sleep (“very well”/“well”/“somewhat” rested) increased from 46.9% (BL) to 90.0% (EOT). Likewise, mean (SD) rating of self-reported sleepiness decreased from 5.1 (2.0) at BL to 3.8 (1.9) at EOT. Conclusion Following open-label LXB treatment, participants with narcolepsy reported improvements in sleep quality and feeling more rested and less sleepy upon awakening. Support (if any) Jazz Pharmaceuticals
0785 Real-World Evaluation of Agent Longevity and Satisfaction in the Treatment of Residual Sleepiness in Patients with Obstructive Sleep Apnea
Seo, Heather, Auger, R. Robert , Roberts, Jessica, Seo, Heather, Morgenthaler, Timothy I.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A340-A340

10.1093/sleep/zsaf090.0785 Get It

Abstract Introduction Residual excessive daytime sleepiness (RES) despite effective positive airway pressure (PAP) therapy for obstructive sleep apnea (OSA) is a clinical problem impacting quality of life and daily function. Wake-promoting agents (WPAs) such as modafinil, armodafinil, and solriamfetol have demonstrated efficacy in reducing RES in randomized controlled trials (RCTs); however, their effectiveness in typical sleep clinic populations remains underexplored. This study aimed to evaluate the efficacy, safety, and tolerability of these WPAs in real-world clinical settings. Methods This retrospective study analyzed electronic health records of 69 randomly selected, consenting patients with OSA who are on PAP therapy and a WPA at Mayo Clinic from 9/19/2019 to 9/19/2024. Researchers reviewed charts for treatment indication, duration, adverse effects, and response (categorized as “complete,” “partial,” or “poor”). Therapy longevity was assessed using initiation, refill, and discontinuation data. Outcomes were analyzed with paired t-tests, chi-square tests, and regression models. Results Of 69 patients, 45 were excluded because: WPA use before observation period (24), off-label WPA use (13), WPA use before CPAP (3), or other (5). Off-label reasons included neurologic-condition-related fatigue (6), depression augmentation (5), and autoimmune-condition-related fatigue (2). 24 patients were on WPAs for RES with PAP-treated OSA, including 3 with mixed indications, and were included in analyses. The median age was 65 (IQR 11). BMI at OSA diagnosis was 33.6 (IQR 6.4). Most subjects were male (75%). Initial Epworth Sleepiness Scale scores (ESS) were 12.3±1.1. ESS at the first WPA prescription were 15.4±0.9 (p=0.04). Most patients (83.3%) started on modafinil. Of the 4 patients who started on armodafinil or solriamfetol, chart review showed a previous trial of modafinil without benefit. After optimizing the initial WPA dosage, ESS improved by 3.3±1.4 points (p=0.04) to 12.1 ±1.2. Side effects limited WPA use in 20.8% of patients. Median first WPA duration was 141 days (IQR 53-280) with no significant difference between these WPAs (p=0.81). Conclusion Although WPAs have narrowly defined approved indications, they are often prescribed off-label for comorbidities. Unlike straightforward use in RCTs, real-life use is more complicated. Patients prescribed WPAs for the targeted approved indication show statistically significant benefits, although adverse effects limited their use for some. Support (if any)